Active Surveillance for Low-risk Papillary Thyroid Carcinoma-Reply

Allen S Ho^{1

2}, Wendy L Sacks^{1

3}, Zachary S Zumsteg^{1

4}

Affiliations

¹ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
² Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
³ Division of Endocrinology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
⁴ Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.

Comment

Allen S Ho et al. JAMA Oncol. 2023.

. 2023 May 1;9(5):722-723.

doi: 10.1001/jamaoncol.2023.0006.

Allen S Ho^{1

2}, Wendy L Sacks^{1

3}, Zachary S Zumsteg^{1

4}

¹ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
² Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
³ Division of Endocrinology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
⁴ Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.

No abstract available

Comment on

Active Surveillance for Low-risk Papillary Thyroid Carcinoma.
Yang S, Tan M, Xu X. Yang S, et al. JAMA Oncol. 2023 May 1;9(5):722-723. doi: 10.1001/jamaoncol.2023.0003. JAMA Oncol. 2023. PMID: 36862418 No abstract available.